Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

Summary

This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab and hyaluronidase-fihj with pomalidomide may help control the disease in patients with relapsed multiple myeloma.

Timeline

Start

2019-04-11

Primary completion

2025-10-09

Completion

2025-10-09

Outcome

Outcome not reported

Stopped: “\<75% participation”

Drugs

Indications